Five-Year Multicenter Cohort Study of Vaginal Microbiome and STIs Progression

November 19, 2026 updated by: Muxuan Chen, Shenzhen Maternity & Child Healthcare Hospital

A Five-Year Longitudinal Follow-Up Study on Vaginal Microbiome Characteristics and Their Association With Reproductive Tract STIs and Cervical Lesion Progression Based on a Multicenter Cohort

  1. To elucidate the long-term impact of vaginal microbiome and the dynamic trends of its characteristics across 5 years follow-up visits on the clinical outcomes of sexually transmitted infections (STIs).
  2. To determine the long-term effects of specific microbial infections (Up6, MH) and vaginal microbiome characteristics on the progression of STIs.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This multicenter, observational study is a 5-year longitudinal follow-up extending the CALM2004 cohort. It aims to enroll 7,574 women aged 18-60 to investigate the long-term impact of vaginal microbiome characteristics and sexually transmitted infections (STIs) on cervical lesion progression. By collecting vaginal secretions, and blood samples, the study will evaluate the 5-year cumulative incidence of CIN2+ and determine how specific microbial infections (e.g., Up6, MH) influence clinical outcomes, providing high-level evidence for cervical cancer prevention strategies.

Study Type

Observational

Enrollment (Estimated)

7574

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China
        • Peking University First Hospital
        • Contact:
          • Bingbing Xiao, Doctor
    • Fujian
      • Fuzhou, Fujian, China
        • Fujian Maternity and Child Health Hospital
    • Gansu
      • Lanzhou, Gansu, China
        • The First Hospital of Lanzhou University
        • Contact:
          • Haitao Yu, Doctor
      • Lanzhou, Gansu, China
        • Gansu Provincial Hospital
        • Contact:
          • Lianhua Wei, Doctor
    • Guangdong
      • Chaozhou, Guangdong, China
        • Chaozhou Central Hospital
        • Contact:
          • Fen lin, Doctor
      • Foshan, Guangdong, China
        • Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine
        • Contact:
          • Chaoxin Jiang, Doctor
      • Guangzhou, Guangdong, China
        • The First Affiliated Hospital, Sun Yat-sen University
        • Contact:
          • Bin Huang, Doctor
      • Guangzhou, Guangdong, China
        • Nanfang Hospital, Southern Medical University
        • Contact:
          • Dehua Sun, Doctor
      • Guangzhou, Guangdong, China
        • The Fifth Affiliated Hospital of Southern Medical University
        • Contact:
          • Xiaoyan Li, Doctor
      • Guangzhou, Guangdong, China
        • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
        • Contact:
          • Yingchun Zhou, Doctor
      • Guangzhou, Guangdong, China
        • The Fifth Affiliated Hospital of Guangzhou Medical University
        • Contact:
          • Liang Peng, Doctor
      • Guangzhou, Guangdong, China
        • The Third Affiliated Hospital of Southern Medical University
        • Contact:
          • Xuefeng Wang, Doctor
      • Guangzhou, Guangdong, China
        • The Third Affiliated Hospital of Guangzhou University of Chinese Medicine
        • Contact:
          • Kewei Zhao, Doctor
      • Guangzhou, Guangdong, China
        • Zhujiang Hospital of Southern Medical University
      • Guangzhou, Guangdong, China
        • Guangzhou Baiyun District Taihe People's Hospital
      • Huizhou, Guangdong, China
        • Huizhou Municipal Central Hospital
        • Contact:
          • Xianjin Wu, Doctor
      • Shaoguan, Guangdong, China
        • Yuebei People's Hospital
        • Contact:
          • Pingsen Zhao, Doctor
      • Shenzhen, Guangdong, China, 518028
        • Shenzhen Maternity & Child Healthcare Hospital
        • Contact:
          • Yuting Dai
          • Phone Number: 0755-82869849
      • Shenzhen, Guangdong, China
        • Luohu District People's Hospital
      • Shenzhen, Guangdong, China
        • Southern Medical University Shenzhen Hospital
        • Contact:
          • Hongwei Zhou, Doctor
      • Shenzhen, Guangdong, China
        • The Seventh Affiliated Hospital, Sun Yat-sen University
        • Contact:
          • Zhaofan Luo, Doctor
      • Zhongshan, Guangdong, China
        • Zhongshan Xiaolan People's Hospital
        • Contact:
          • Wandang Wang, Doctor
      • Zhuhai, Guangdong, China
        • Zhuhai Maternal and Child Health Hospital
    • Guangxi
      • Nanning, Guangxi, China
        • The First Affiliated Hospital of Guangxi Medical University
        • Contact:
          • Faquan Lin, Doctor
    • Guizhou
      • Guiyang, Guizhou, China
        • Affiliated Hospital of Guizhou Medical University
        • Contact:
          • Fan Lu, Doctor
      • Zunyi, Guizhou, China
        • Zunyi First People's Hospital
        • Contact:
          • Kaifeng Wu, Doctor
    • Hainan
      • Haikou, Hainan, China
        • Hainan General Hospital
        • Contact:
          • Bo Wang, Doctor
    • Heilongjiang
      • Mudanjiang, Heilongjiang, China
        • Hongqi Hospital Affiliated to Mudanjiang Medical University
        • Contact:
          • Chunxia Guo, Doctor
      • Qiqihar, Heilongjiang, China
        • Qiqihar First Hospital
    • Henan
      • Zhengzhou, Henan, China
        • Henan Provincial People's Hospital
        • Contact:
          • Jing Zhao, Doctor
    • Inner Mongolia
      • Hohhot, Inner Mongolia, China
        • Inner Mongolia Autonomous Region Maternal and Child Health Hospital
        • Contact:
          • Jing Sha, Doctor
    • Jiangsu
      • Lianyungang, Jiangsu, China
        • The Second People's Hospital of Lianyungang
        • Contact:
          • Wei Liang, Doctor
    • Jilin
      • Jilin City, Jilin, China
        • Jilin City Central Hospital
        • Contact:
          • Guijie Zhang, Doctor
    • Liaoning
      • Shenyang, Liaoning, China
        • The First Hospital of China Medical University
        • Contact:
          • Ruizhe Wang, Doctor
    • Ningxia
      • Yinchuan, Ningxia, China
        • General Hospital of Ningxia Medical University
        • Contact:
          • Feng Li, Doctor
    • Qinghai
      • Xining, Qinghai, China
        • Qinghai Red Cross Hospital
        • Contact:
          • Dengyun Ma, Doctor
    • Shandong
      • Jinan, Shandong, China
        • Jinan Central Hospital
        • Contact:
          • Shuyi Han, Doctor
      • Jinan, Shandong, China
        • Shandong Provincial Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Shanghai East Hospital, Tongji University
        • Contact:
          • Jingxin Cheng, Doctor
    • Shanxi
      • Changzhi, Shanxi, China
        • Changzhi People's Hospital
        • Contact:
          • Guoxiang Zhang, Doctor
    • Sichuan
      • Dazhou, Sichuan, China
        • Dazhou Integrated Traditional Chinese and Western Medicine Hospital
        • Contact:
          • Xuesu He, Doctor
      • Luzhou, Sichuan, China
        • Affiliated Hospital of Southwest Medical University
        • Contact:
          • Jinbo Liu, Doctor
    • Tibet
      • Lhasa, Tibet, China
        • Tibet Autonomous Region People's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

A total of 7,574 women aged 18-60 years who previously participated in the baseline of the CALM2004 multicenter cohort study will be recruited for this 5-year longitudinal follow-up. This is a multicenter study, and participants will be recruited through targeted invitations from the research team members. The study population consists of women with a broad spectrum of baseline vaginal microecological statuses and varying risks of STIs and cervical lesions.

Description

Inclusion Criteria:

  1. Female aged 18 to 60 years.
  2. Participants who previously participated in the baseline of the CALM2004 study.
  3. Volunteers who are recruited through targeted invitations and consent to participate in this study.

Exclusion Criteria:

  1. Pregnant women.
  2. Received treatment for reproductive tract infections or sexually transmitted infections (STIs) within the past month.
  3. Used broad-spectrum antibiotics, local genital probiotics, or vaginal suppositories within the past month.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
CALM2004 Follow-up Cohort

A total of 7,574 women aged 18-60 who previously participated in the CALM2004 baseline study will be enrolled for a 5-year longitudinal follow-up. Participants will undergo comprehensive assessments including questionnaires, vaginal secretion collection for metagenomic sequencing, cervical exfoliated cells for TCT and STI nucleic acid testing, and venous blood testing. No specific interventions will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative incidence of CIN2+ at 5 years
Time Frame: 5 years

The incidence rate of histologically confirmed Cervical Intraepithelial Neoplasia grade 2 or 3 (CIN2/3) or invasive cervical cancer occurring for the first time during the follow-up period, among participants who had no cervical lesions or were <CIN2 at baseline

5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
New incidence and progression rates of ASC-US+ cytological abnormalities
Time Frame: 5 years

ASC-US+ new incidence: First occurrence of ASC-US or higher cytological abnormality during follow-up in participants with normal baseline cytology. ASC-US+ progression: First occurrence of LSIL/HSIL or higher cytological abnormality during follow-up in participants with baseline ASC-US. Cytology is evaluated according to the Bethesda System for Reporting Cervical Cytology.

5 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
HPV and STI incidence, clearance, and persistent/recurrent infection rates
Time Frame: 5 years

HPV new infection: baseline negative, follow-up positive; HPV clearance: baseline positive, follow-up negative; HPV persistent infection: same genotype positive at both baseline and follow-up. STI new infection: baseline negative, follow-up positive; STI clearance: baseline positive, follow-up same genotype negative; STI recurrent infection: same genotype positive at both baseline and follow-up.

5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Chair: Hongwei Zhou, Doctor, Shenzhen Hospital of Southern Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 20, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

December 30, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 19, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CALM2004-5

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.